Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-559-3 | CAS number: 122-63-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
Repeated dose toxicity ,Oral : The no observed adverse effect level (NOAEL) for repeated dose toxicity study for benzyl propionate was estimated to be 520.25 mg/kg/day when administered orally in feed to rat in a subchronic study of 90 days.
Repeated dose toxicity, Inhalation: The presence of benzyl propionate in cigarette at 13 ppm did not significantly change the type or extent of toxicologic effects observed in rodents inhaling cigarette smoke.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Principles of method if other than guideline:
- Repeated Dose 28-day Oral Toxicity Study of Benzyl Propionate in the Rat.
- GLP compliance:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Details on test animal
TEST ANIMALS
- Source: National Institute of Biosciences, Pune.
- Age at study initiation: 6 to 8 weeks old
- Weight at study initiation:
Male 169.50 gg
Female 152.35 g
- Fasting period before study: No data available
- Housing: Animals were housed in polycarbonate cages. Three rats of same sex were housed together in each cage of size 39 cm X 28 cm X 14 cm. Paddy husk was used as bedding material.
- Diet (e.g. ad libitum): Rodent feed supplied by the Nutrivet Life Sciences, Pune, was provided ad libitum from individual feeders on cage top.
- Water (e.g. ad libitum): Water was provided ad libitum from individual bottles attached to the cages. Water was from a local source and passed through the reverse osmosis membrane before use.
- Acclimation period: 5 days prior to dosing.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3°C (actual range: 19.5 °C to 22.8 °C)
- Humidity (%):30% to 70% (actual range: 53.3% to 58.1%).
- Air changes (per hr): Ten air changes per hour of 100% fresh air that has been passed through the HEPA filters.
- Photoperiod (hrs dark / hrs light): An artificial light and dark cycle of 12 - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- Details on oral exposure
PREPARATION OF DOSING SOLUTIONS: Benzyl Propionate was diluted with Corn oil for
preparation of dosing solution(s).
DIET PREPARATION
- Rate of preparation of diet (frequency): No data available
- Mixing appropriate amounts with (Type of food): No data available
- Storage temperature of food: No data available
VEHICLE
- Justification for use and choice of vehicle (if other than water): No data available
- Concentration in vehicle:
The solution(s) were prepared at concentrations of 0, 25, 50 and 100 mg/ml such that dosage of 0 (vehicle), 250, 500 and 1000 mg/kg bw/day.
- Amount of vehicle (if gavage):
0.00 mg/ml/day, 26.60 mg/ml/day, 52.38 mg/ml/ day and 105.27 mg/ml/day.
- Lot/batch no. (if required): No data available
- Purity: No data available - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Analysis for concentration and stability of Benzyl Propionate were conducted at Subcontracted Laboratory. Test item formulation samples prepared day 1 (pre-dosing) were sent to Subcontracted Laboratory.
- Duration of treatment / exposure:
- 28 days consecutively
- Frequency of treatment:
- Once daily
- Remarks:
- Doses / Concentrations:
0 (vehicle), 250, 500 and 1000 mg/kg bw/day.
Basis:
actual ingested - No. of animals per sex per dose:
- Control: 6 male, 6 female
250 mg/kg bw/day: 6 male, 6 female
500 mg/kg bw/day: 6 male, 6 female
100 0mg/kg bw/day: 6 male, 6 female - Control animals:
- yes, concurrent vehicle
- Details on study design:
- Details on study design
- Dose selection rationale:
Based on results from a preliminary 14-day study there was no chenge in the survivel, body weight, Daily clinical observations and Gross pathological examination of 1000 mg/kg/bw/day group. Based on these results, the 28 day study dose levels were finalized as 0 mg/kg, 250 mg/kg, 500 mg/kg and 1000 mg/kg body weight.
- Rationale for animal assignment (if not random): Animals were randomized by sex and body weight
- Rationale for selecting satellite groups: No data available
- Post-exposure recovery period in satellite groups: No data available
- Section schedule rationale (if not random): No data available - Observations and examinations performed and frequency:
- Observations and examinations performed & frequency
CAGE SIDE OBSERVATIONS: Yes
- Time schedule: No data available
- Cage side observations checked in table [No.?] were included. : Rats were observed for Behavior, Alterations, Vocalizations, Respiration and Palpebral closure.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Once daily, At least once a week there after until
BODY WEIGHT: Yes
- Time schedule for examinations: On the day of randomization, first day of dosing, weekly thereafter and a fasting body weight at scheduled sacrifice on day 29.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): No data available
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: No data available
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No data available
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: Yes / No / No data
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No data available
- Time schedule for examinations: No data available
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: Once a day
- Dose groups that were examined: 0 mg/kg, 250 mg/kg, 500 mg/kg and 1000 mg/kg bw/day.
HAEMATOLOGY: Yes, By using Beckman Coulter haematology analyzer.
- Time schedule for collection of blood:
At termination.
- Anaesthetic used for blood collection: No data available
- Animals fasted: Yes, overnight fasted prior to sampling.
- How many animals: Blood collected from all rats of 0 mg/kg, 250 mg/kg, 500 mg/kg and 1000 mg/kg bw/day group at termination.
- Parameters checked in table [No.?] were examined. : Hemoglobin, Red Blood Corpuscles, Hematocrit, Mean Corpuscular Volume, Mean Corpuscular Hemoglobin, Mean Corpuscular Hemoglobin Concentration, Platelets, White Blood Corpuscles, Neutrophils, Lymphocytes, Eosinophils, Monocytes, Basophil and Prothrombin time were checked, Table No.H; Appendix No.VII.
CLINICAL CHEMISTRY: Yes, By using Dimension XpandPlus and Acculyte 5P.
- Time schedule for collection of blood: At termination.
- Animals fasted: Yes, overnight fasted prior to sampling.
- How many animals: Blood collected from all rats of 0 mg/kg, 250 mg/kg, 500 mg/kg and 1000 mg/kg bw/day group at termination.
- Parameters checked in table [No.?] were examined. : Total Protein, Blood Urea Nitrogen, Urea Nitrogen, Alanine Aminotransferase, Aspartate Aminotransferase, Alkaline Phosphatase, Gamma Glutamyl Transferase, Glucose, Calcium, Phosphorous, Albumin, Total Bilirubin, Creatinine , Total Cholesterol, Triglycerides, Globulin Calculated
Sodium, Potassium, Chloride were checked, Table No.I; Appendix No.VIII.
URINALYSIS: No data available
- Time schedule for collection of urine: No data available
- Metabolism cages used for collection of urine: No data available
- Animals fasted: No data available
- Parameters checked in table [No.?] were examined. : No data available
NEUROBEHAVIOURAL EXAMINATION: No data available
- Time schedule for examinations: No data available
- Dose groups that were examined: No data available
- Battery of functions tested: sensory activity / grip strength / motor activity / other: Yes
OTHER: Viability, Behavior in Home cage, Vocalizations, Respiration, Palpebral closure, Handling Observations, Urination, Defecation, Prominence of Eye, Lacrimation, Salivation, Piloerection, Examination of Skin / Fur, Stereotype Behaviour, Rearing (Rears), Clonic and Tonic Movements and Severity of Gait were observed. - Sacrifice and pathology:
- Sacrifice and pathology
GROSS PATHOLOGY: Yes
Gross necropsy was conducted. All the animals of 0 mg/kg, 250 mg/kg, 500 mg/kg and 1000 mg/kg/bw/day group were sacrificed and gross lesions were noted.
HISTOPATHOLOGY: Yes
Control and treated at the highest dose level of 1000 mg/kg were subjected to sacrifice.
Organs examined: Adrenals, Aorta, Brain (cerebrum, cerebellum and pons), Caecum, Cervix, Colon, Duodenum, Epididymides, Eyes, Heart, Ileum, Jejunum, Kidneys, Liver, Lungs, Mesenteric Lymphnodes, Oesophagus, Ovaries, Pancreas, Pituitary gland, Pharyngeal Lymphnodes, Prostate, Rectum, Skeletal Muscles, Skin with Mammary Gland, Spleen, Sternum with bone marrow, Sciatic Nerve, Spinal Cord (Cervical, mid thoracic and lumbar), Stomach, Seminal Vesicles with Coagulation Gland, Testes, Thymus, Thyroid, Trachea, Vagina, Urinary Bladder and Uterus of 1000 mg/kg/bw/day group.
- Statistics:
- Data were analyzed for reporting group means and standard deviations with significance between the controls and treated groups, using in-house developed and validated MS-Excel 2003 based statistical software. All the parameters characterized by continuous data such as body weight, per cent body weight change, feed consumption, organ weight, relative organ weight, haematological and clinical chemistry data were subjected to Bartlett’s test to meet the homogeneity of variance before conducting Analyses of Variance (ANOVA) and Dunnett’s t-test. Where the data did not meet the homogeneity of variance, Student’s t-test was performed to calculate significance.
Significance was calculated at 1% as well as 5% level and indicated in the summary tables as follows:
* = Significant than control at 95% level of confidence (p≤ 0.05).
** = Significant than control at 99% level of confidence (p≤ 0.01). - Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- Clinical signs and mortality
Clinical signs :
Daily clinical observations did not reveal any signs of toxicity in male and female animals from of 0 mg/kg, 250 mg/kg, 500 mg/kg and 1000 mg/kg bw/day dose groups
Mortality:
No mortality were observed in any of the traeted groups of 0 mg/kg, 250 mg/kg, 500 mg/kg and 1000 mg/kg bw/day.
Body weight and weight gain All the rat of 0 mg/kg, 250 mg/kg, 500 mg/kg and 1000 mg/kg/bw/day dose groups exhibited normal body weight gain at the end of the study period of 28 days.
Food consumption and compound intake Food intake of animals for control and 250 mg/kg, 500 mg/kg and 1000 mg/kg /bw/day dose groups were found to be normale throughout the study period of 28 days.
Food efficiency: No data available
Water consumption and compound intake No data available
Opthalmoscopic examination No data available
Haematology Increase in the values of Hb of male rats dosed at 500 mg/kg and 1000 mg/kg, MCHC of male rats dosed at 500 mg/kg, Total WBC of male rats dosed at 1000 mg/kg were observed.
Plateles of female rats dosed at 1000 mg/kg were also increase. The increase in the values of different parameters is within the normal laboratory limits.
Clinical chemistry Increase level of Sodium in male rats dosed at 250 mg/kg and 1000 mg/kg of Benzyl Propionate.
Chloride levels significantly increase in male rats dosed at 250 mg/kg of Benzyl Propionate.
Statistically significant increase of Calcium levels in female rats dosed at 250 mg/kg and increase Bilirubin levels in female rats dosed at 500 mg/kg of Benzyl Propionate were found well increase level of Sodium in female rats dosed at 250 mg/kg, 500 mg/kg and 1000 mg/kg were observed.
Statistically significant decrease of Alkaline Phosphatase levels in female rats dosed at 250 mg/kg, decrease level of Potassium in female rats dosed at 250 mg/kg and 1000 mg/kg and decrease Chloride levels in female rats dosed at 1000 mg/kg Benzyl Propionate were observed.
Although there was an increase/decrease in the values the deviations were within the range of normal laboratory limits.
Urinanalysis: No data available
Neurobehaviour: No data available
Organ weights: Organ weight of 100 mg/kg/bw/day dose group male animals sacrificed on day 29, was found to be comparable with that of controls.
Organ weight of female animals sacrificed on day 29, revealed increased relative weights of liver, ovaries and lungs of 1000 mg/kg dose group.The significant changes in organ weights were observed in female animals from high dose group, the effects are not related to Benzyl Propionate.
Gross pathology All the treatment groups control and 250 mg/kg/bw/day, 500 mg/kg/bw/day and 1000 mg/kg/bw/day of Benzyl Propionate dus not showe any chengs.
Histopathology: Minimal focal to multifocal periportal mononuclear cell infiltration in the liver; minimal interstitial haemorrhages in the kidneys; minimal alveolar haemorrhages and/or alveolar histiocytosis in the lungs; minimal multifocal haemosiderosis and/or diffused congestion in spleen; minimal eosinophilic infiltration and/or luminal dilatation in uterus; minimal luminal seminal coagulum in the urinary bladder; minimal dilatation of zona reticularis and/or presence of accessory adrenocortical tissue in adrenals; minimal multifocal haemorrhages in thymus; presence of ultimobranchial cysts in thyroid; in male or female animals of control and 1000 mg/kg/bw/day dose group. All the changes observed in the control and 1000 mg/kg/bw/day dose treatment group animals were similar and the effect observed are not due to Benzyl Propionate. - Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Based on Clinical biochemistry, Organ weight, Gross pathological, Histopathology and survival.
- Critical effects observed:
- not specified
- Conclusions:
- NOAEL was considered to be 1000 mg/kg bw/day when Sprague-Dawley rats exposed to Benzyl Propionate orally foe 28 days.
- Executive summary:
A subacute study was conducted to evaluate the toxic effects of repeated administration of Benzyl Propionate in male and female Sprague-Dawley rats by gavage. Benzyl Propionate was administered to 6 animals/sex/species in Corn oil at doses of 0,250,500 and 1000 mg/kg/bw/day for 28 days. All rats of 250,500 and 1000 mg/kg/bw/day dose group Survive though-out the study, Benzyl Propionate have no effect on mortality. Blood samples for Clinical Biochemistry and Haematology were collected. No abnormalities occurred that could be directly attributed to Benzyl Propionate treatment. Although significant change in relative weights of liver, ovaries and lungs of female were observed in 1000 mg/kg/bw/day dose groups. No Benzyl Propionate related gross pathological or histological changes were seen and findings were not Benzyl Propionate dependent and hence considered to be of no toxicological importance. Therefore NOEAL for repeated dose toxicity study was considered to be 1000 mg/kg/bw/day in male and female Sprague-Dawley rats when exposed to Benzyl Propionate by oral route for 28 days.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Qualifier:
- according to guideline
- Guideline:
- other:
- Principles of method if other than guideline:
- Sprague-Dawley rats were exposed by nose-only inhalation for 1 h/day, 5 days/wk for 13 wk to smoke from the test or reference cigarettes already described, or to air only, and necropsied after 13 wk of exposure or following 13 wk of recovery from smoke exposure
- GLP compliance:
- not specified
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories
- Age at study initiation: 6-7 wks
- Housing: During the 13-wk exposure period, the animals were housed in individual stainless-steel cages on open racks. During the recovery period, the animals were housed in individual polycarbonate cages bedded with ALPHA-dri alpha cellulose bedding.
- Acclimation period: 24 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C):
- Humidity (%):
- Air changes (per hr):
- Photoperiod (hrs dark / hrs light): - Route of administration:
- inhalation
- Type of inhalation exposure:
- nose only
- Vehicle:
- air
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: Animal exposures were conducted in AMESA exposure units
- System of generating particulates/aerosols: The smoke exposure machines were designed to contain 30 cigarettes on a smoking head that rotated 1 revolution per minute. A vacuum port aligned with, and drew a puff from, one test or reference cigarette at a time as the head rotated.
- Temperature, humidity, pressure in air chamber:
- Air flow rate: Air was drawn through the vacuum port by a peristaltic pump operating at a flow rate of ∼1.05 L/min,creating a 2-s, 35-ml puff through each cigarette once each minute. The smoke vacuum flow rate was regulated by a concentration control unit consisting of a real-time aerosol monitor [(RAM)-1], a computer, and an electronic flow controller.
TEST ATMOSPHERE
- Brief description of analytical method used: The exposure units contained 3 tiers, each with 24 animal exposure ports. The exposure ports were connected to a delivery manifold, which transferred smoke to the animal breathing zone, and to an outer concentric manifold that drew the exhaled and excess smoke to an exhaust duct. Each cigarette was retained for seven puffs.
- Samples taken from breathing zone: yes/no
VEHICLE (if applicable)
- Justification for use and choice of vehicle:
- Composition of vehicle:
- Type and concentration of dispersant aid (if powder):
- Concentration of test material in vehicle:
- Lot/batch no. of vehicle (if required):
- Purity of vehicle: - Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 13 weeks
- Frequency of treatment:
- 1 h/day, 5 days/wk
- Remarks:
- Doses / Concentrations:
0 or 0.013 mg/L (13 ppm) as a part of 0, 0.06, 0.2 or 0.8 mg/L WTPM of smoke
Basis:
no data - No. of animals per sex per dose:
- 30
- Control animals:
- yes, sham-exposed
- Details on study design:
- Each group of 30 rats/sex was subdivided into 2 groups: 20 rats/sex scheduled for necropsy immediately after 13 wk of exposure (interim sacrifice) and up to 10 rats/sex scheduled for necropsy following 13 wk of recovery from smoke exposure (final sacrifice)
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: All rats were observed twice daily for mortality and moribundity
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Each rat was examined every 4 wk for clinical signs
BODY WEIGHT: Yes
- Time schedule for examinations: Individual body weights were measured during the randomization procedure, on exposure day 1, biweekly thereafter, and at necropsy
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: No
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: During wk 2, 10 and on the day of the 13-wk interim sacrifice
- Anaesthetic used for blood collection: Yes (∼70% CO2)
- Animals fasted: No data
- How many animals: No data
- Parameters examined: white blood cell (WBC) count, red blood cell (RBC) count, hemoglobin (Hb) concentration, volume of packed red cells (VPRC), the red cell indices (mean corpuscular volume [MCV], mean corpuscular hemoglobin [MCH], and mean corpuscular hemoglobin concentration [MCHC]), platelet count, and WBC differential counts.
During wk 2 and 10, samples were analyzed for blood carboxyhemoglobin (COHb)
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: During wk 2, 10 and on the day of the 13-wk interim sacrifice
- Animals fasted: No data
- How many animals: No data
- Parameters examined: urea nitrogen (BUN), creatinine, glucose, total protein, albumin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase(GGT), sodium, potassium, chloride, calcium, phosphorus, total bilirubin, cholesterol, and triglycerides.
During wk 2 and 10, Plasma nicotine was quantitatively determined using gas chromatography/mass spectrometry (GC/MS) with selected ion monitoring
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No
OTHER: No - Sacrifice and pathology:
- A complete necropsy was done on all 13-wk exposure groups and 13-wk recovery group animals
GROSS PATHOLOGY: Yes
All abnormalities were recorded on the individual animal necropsy forms. Lungs, liver, kidneys, testes, adrenals, spleen, brain, and heart from all scheduled sacrifice animals were weighed. These organ weights and the body weights at necropsy were used to calculate organ:body weight ratios. In addition, organ:brain weight ratios were calculated
HISTOPATHOLOGY: Yes
Duplicate slides of nasal tissues, larynx, lung, and trachea were stained with periodic acid-Schiff/Alcian blue (PAS/AB) stains for evaluation of goblet cell populations. The lungs, nasal cavity (four sections), nasopharynx, larynx (three cross sections), trachea (three transverse sections), tracheobronchial lymph nodes, mediastinal (thymic) lymph nodes, heart, and all gross lesions were examined microscopically.
In addition, sections of brain, adrenals, spleen, liver, kidneys, and gonads from animals
in the sham control and the groups exposed to 0.8 mg/L of smoke from the test or reference cigarettes were examined microscopically. - Other examinations:
- Respiratory Function Measurements
Tidal volume (TV), respiratory rate (RR), and minute volume (MV), derived from flow signals from spontaneously breathing animals, were measured in 4 rats/sex/group during wk 2, 8, and 13 using whole-body phethysmography.
Each animal was monitored once during a single exposure period.
Evaluation of Cell Proliferation Rates of Respiratory-Tract Tissues
Cell proliferation rates were measured on respiratory tract tissues collected from 10 rats of each sex from each exposure group and the sham controls necropsied immediately after 13 wk of exposure, using a monoclonal antibody to 5-bromo-2_-
deoxyuridine (BrdU). Tissues evaluated using the BrdU assay included the respiratory epithelium lining the median nasal septum and distal portions of maxillary and nasal turbinates, the transitional epithelium at the base of the epiglottis, the luminal epithelium dorsolateral to the ventral pouch, the luminal epithelium lining the cranial trachea, the luminal epithelium of the mainstem bronchi and adjacent bronchioles, and selected areas of alveolar epithelium - Statistics:
- Body weight, body weight gain, organ:body weight, and organ:brain weight ratios were statistically analyzed using the Xybion PATH/TOX system.
Data homogeneity was determined by Bartlett’s test.
Dunnett’s t-test was performed on homogeneous data to identify differences between each concentration group and the sham control group, and between corresponding concentrations of test and reference cigarette smoke-exposed groups. Nonhomogeneous data were analyzed using a modified t-test.
Respiratory physiology, clinical pathology, COHb, and plasma nicotine data parameters were statistically evaluated using SAS software (Statistical Analysis System, SAS, Inc., Cary, NC).
One-way analysis of variance (ANOVA) between exposure groups was first conducted, followed by Bartlett’s test for homogeneity of variance.
A two-sided Dunnett’s multiple comparison test was employed to determine which exposure groups were different from the controls. An unpaired two-sided t-test was used to compare equivalent exposure groups between cigarette types - Clinical signs:
- no effects observed
- Description (incidence and severity):
- No significant mortality occurred and exposure related adverse clinical signs were absent
- Mortality:
- no mortality observed
- Description (incidence):
- No significant mortality occurred and exposure related adverse clinical signs were absent
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Mean body weights were consistently decreased in male rats and all female smoke-exposed groups were comparable to sham control females throughout the study. Mean body weights of smoke-exposed groups were similar to sham control during the recovery period.
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- There were statistically significant differences in several hematology parameters between test and reference cigarette smoke exposed groups. These differences are not considered to be of toxicologic significance, nor were they exposure related.
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- There were statistically significant differences in several clinical chemistry parameters between test and reference cigarette smoke groups. These differences are not considered to be of toxicologic significance, nor were they exposure related.
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Statistically significant differences in organ weights in groups of smoke-exposed rats were primarily low mean organ weights compared to their respective sham controls.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- Few gross lesions were observed, with no evidence of changes attributable to exposure to smoke from the test or the reference cigarettes
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- Exposure to smoke from reference or test cigarettes induced concentration-related proliferative, metaplastic, and inflammatory microscopic lesions in the respiratory tract after 13 wk of exposure.
- Histopathological findings: neoplastic:
- not specified
- Details on results:
- BODY WEIGHT AND WEIGHT GAIN: Mean body weights were consistently decreased compared to sham controls during the exposure period in male rats exposed to 0.8 mg/L of reference cigarette smoke and in males exposed to all 3 concentrations of test cigarette smoke
HAEMATOLOGY: Whole-blood COHb levels were increased in a graded dose response fashion as a function of exposure concentration for all test and reference cigarette smoke-exposed groups
CLINICAL CHEMISTRY: Plasma nicotine levels increased in a graded dose-response fashion for test and reference males and female groups
HISTOPATHOLOGY: NON-NEOPLASTIC
Hyperplasia of respiratory epithelium lining the anterior nasal cavity was present but was not of statistical significance.
Minimal goblet-cell hyperplasia was observed in the mucosal epithelium lining the median nasal septum in some smoke-exposed and sham control rats. Although not statistically significant, the incidence of nasal goblet cell hyperplasia in male rats exposed to the 0.8-mg/L concentration of smoke from the reference or test cigarette were considered to be toxicologically significant.
Exposure to smoke from the reference or test cigarette induced squamous metaplasia, hyperplasia, and hyperkeratosis of the transitional epithelium lining the base of the epiglottis and the epithelium lining the dorsal border of the ventral pouch and the adjacent laryngeal lumen. - Dose descriptor:
- NOAEL
- Effect level:
- 13 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No alteration in the toxicity of cigarette
- Critical effects observed:
- not specified
- Conclusions:
- The presence of benzyl propionate in cigarette at 13 ppm did not significantly change the type or extent of toxicologic effects observed in rodents inhaling cigarette smoke.
- Executive summary:
Flavoring ingredients such as benzyl propionate are added to tobacco during the manufacture of many types of commercial cigarettes. This study has been carried out to determine the effect of these added ingredients on the toxicity of the resultant smoke.
Benzyl propionate was added at an level of 13 ppm in the cigarette. Sprague-Dawley rats were exposed by nose-only inhalation for 1 h/day, 5 days/wk for 13 wk to smoke from the test or reference cigarettes already described, or to air only, and necropsied after 13 wk of exposure or following 13 wk of recovery from smoke exposure.
Exposure to smoke from reference or test cigarettes induced increases in blood carboxyhemoglobin (COHb) and plasma nicotine, decreases in minute volume, differences in body or organ weights compared to air controls, and a concentration-related hyperplasia, squamous metaplasia, and inflammation in the respiratory tract. All these effects were greatly decreased or absent following the recovery period.
Comparison of rats exposed to similar concentrations of test and reference cigarette smoke indicated no difference at any concentration. In summary, the results did not indicate any consistent differences in toxicologic effects between smoke from cigarettes containing the flavoring ingredients and reference cigarettes. Thus, addition of benzyl propionate did not result in an alteration in the toxicity of the cigarette
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEC
- 13
- Study duration:
- subchronic
- Species:
- rat
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Repeated dose toxicity: oral route
Based on the various studies available with Klimish rating 2 and 4 for the read across substances for CAS: 122-63-4 based on the category approach of organic functional group along with similar mechanistic approach and having structural similarities defined by QSAR toolbox. This data is combined with the prediction done using the QSAR toolbox for the target chemical based on similar category approach, the results is summarized as follows:
Sr. No |
End point |
Value |
Species |
Route |
Duration |
Effects |
Remarks |
1 |
NOAEL |
520.25 mg/ kg bw/ d |
Male/female Rat |
Oral: feed |
90 days |
No effect on body weight and feed consumption |
Predicted data for target chemical |
2 |
NOAEL
LOAEL
|
25000 ppm (1750 mg/kg bw/d for males and 1870 mg/kg bw/d for females)
50000 ppm (3900 mg/kg bw/d for males and 4500 mg/kg bw/d for females) |
Male/female Rat |
Oral: feed |
13 weeks (91 days) |
No effect feed consumption
Mortality, decreased feed consumption, tremors and ataxia. |
Data from NTP report for CAS: 140-11-4 |
3 |
NOAEL
LOAEL
|
6000 ppm (460 mg/Kg bw /d for males and 480 mg/Kg bw /d for females)
12000 ppm (900 mg/Kg bw /d for males and 930 mg/Kg bw /d for females) |
Male/female Rat |
Oral: feed |
2 years |
No effect on body weight and feed consumption
Decreased body weight and feed consumption |
Data from NTP report for CAS: 140-11-4 |
Based on the studies summarized in the above table with oral routes it can be observed that NOAEL values estimated was 520.25 mg/Kg bw/ d. Also the NOAEL value varies from 460 - 1870 mg/kg bw/d and the LOAEL varies from 900 – 4500 mg/kg bw/day. The effects observed at these doses are listed as follows:
· Effects on mortality, decreased feed consumption, tremors and ataxia.
. Decreased body weight and feed consumption
Thus based on above discussion it can be concluded that substance CAS: 122-63-4 is expected to show the similar toxicological effect based on the effects observed on the other category members. Since the no effective dose value (NOAEL) is 520 mg/Kg bw/d thus based on this value it can be concluded that substance CAS: 122-63-4 is considered to be not toxic.
Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:
NOAEL was considered to be 1000 mg/kg bw/day when Sprague-Dawley rats exposed to Benzyl Propionate orally foe 28 days.
Justification for selection of repeated dose toxicity inhalation - systemic effects endpoint:
The presence of benzyl propionate in cigarette at 13 ppm did not significantly change the type or extent of toxicologic effects observed in rodents inhaling cigarette smoke.
Justification for classification or non-classification
Based on the available data, the substance benzyl propionate is not classified as toxic by the repeated exposure via oral and inhalation route.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
